Results of five-year monitoring of data from the register of children with juvenile idiopathic arthritis in Moscow
Authors:   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Sevostyanov V.K. ,   The Research Institute for health organization and medical management, Moscow, Russian Federation, Riabtseva A.I. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Kakorina E.P. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation,   M.F.Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russian Federation, Babich N.B. ,   Rostov State Medical University, Rostov-on-Don, Russian Federation, Severgina U.S. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Balashov S.L. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Novikov A.S. ,   V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, Razumov Yu.Yu. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Lototskaya P.S. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Zholobova E.S. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation,   Moscow Center of Pediatric Rheumatology, Morozov Children's City Clinical Hospital, Moscow Healthcare Department, Moscow, Russian Federation
Published: February 2022

Objective. To perform a 5-year (2016–2020) monitoring of data from the register of children with juvenile idiopathic arthritis (JIA) in Moscow. Patients and methods. We conducted an observational, descriptive, cross-sectional study involving 1220 JIA patients aged 0 to 17 years. The sample included 783 girls (64.2%) and 437 boys (35.8%). Results. We found that the prevalence of JIA among children aged 0–17 years in Moscow doubled over the last 5 years: from 28.7 to 55.8 per 100,000. There was a minor increase in the primary incidence of JIA: from 9.5 to 12.5 per 100,000. There were some changes in the JIA structure, including a 7% reduction in the proportion of polyarticular seronegative JIA and an 8.3% reduction in the proportion of systemic JIA, along with an 19.4% increase in the proportion of oligoarticular JIA. We observed no significant differences in the structure of basic anti-inflammatory therapy. Approximately 80% of patients received basic therapy; the drug of choice was methotrexate (86.9%). Tumor necrosis factor-α inhibitors (such as etanercept, adalimumab, and golimumab) were the most commonly used biologicals. The frequency of etanercept use increased from 44.9% to 50.7% over 5 years. Conclusion. Regional registers of patients with rheumatic diseases are the most important tool for surveillance, assessment of JIA structure, course, and comorbidities, identification of patients at risk for disability, planning pharmacotherapy, and calculating its cost. Key words: juvenile arthritis, prevalence, incidence, dynamics of the structure of juvenile arthritis, dynamics of basic anti-rheumatic therapy, dynamics of therapy with biologicals